Valneva's Clostridium difficile vaccine candidate - VLA84
Valneva aims to develop a vaccine for the prevention of Clostridium difficile, a leading cause of life threatening, healthcare associated infections worldwide.
Clostridium difficile (C. difficile)
is the most common infectious cause for nosocomial diarrhea in Europe and the US. There are an estimated 450,000 cases of C. difficile
in the US annually and no vaccine against the disease is commercially available.
Valneva successfully completed Phase 2 development of its prophylactic vaccine candidate against Clostridium difficile
infection, confirming previously announced positive topline data. The vaccine candidate VLA84 is Phase 3 ready.
Valneva seeks to partner its Clostridium difficile
vaccine candidate. At this point, however, potential partners are hesitant about the level of investment required to fund a Phase 3 clinical trial. Therefore, the Company reviewed its development and partnering approach. Valneva will consider using the first CDI vaccine approval and to conduct a head to head, non-inferiority Phase 3 trial, based on an immunological correlate that is expected to substantially improve the investment – risk profile of an in-house, or partnered, development to market.
Read more about Clostridium difficile
The Company estimates that the total market potential for prophylactic C. difficile products may exceed $1 billion annually.
PR: Valneva Announces Successful Completion of Phase II for Clostridium Difficile Vaccine Candidate
This program is supported by the Vienna Business Agency.